Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Isoflurane Sedation on the ICU in Cardiac Arrest Patients Treated With Targeted Temperature Management: An Observational Propensity-Matched Study

Krannich, Alexander MSc1; Leithner, Christoph MD2; Engels, Martin MD1; Nee, Jens MD1; Petzinka, Victor1; Schröder, Tim MD1; Jörres, Achim MD, PhD1; Kruse, Jan MD1; Storm, Christian MD, PhD1

doi: 10.1097/CCM.0000000000002185
Online Clinical Investigations
Buy
SDC

Objective: Targeted temperature management after cardiac arrest requires deep sedation to prevent shivering and discomfort. Compared to IV sedation, volatile sedation has a shorter half-life and thus may allow more rapid extubation and neurologic assessment.

Design: Observational analysis of clinical data.

Setting: University hospital, medical ICU.

Patients: Four hundred thirty-two cardiac arrest survivors underwent targeted temperature management; of those, 110 were treated with volatile sedation using an anesthetic conserving device and isoflurane, and 322 received standard IV sedation.

Intervention: No intervention.

Measurement and Main Results: A matched pairs analysis revealed that time on ventilator (difference of median, 98.5 hr; p = 0.003) and length of ICU stay (difference of median, 4.5 d; p = 0.006) were significantly shorter in patients sedated with isoflurane when compared with IV sedation although no differences in neurologic outcome (45% of patients with cerebral performance category 1–2 in both groups) were observed. Significant hypercapnia occurred more frequently during anesthetic conserving device use (6.4% vs 0%; p = 0.021).

Conclusions: Volatile sedation is feasible in cardiac arrest survivors. Prospective controlled studies are necessary to confirm the beneficial effects on duration of ventilation and length of ICU stay observed in our study. Our data argue against a major effect on neurologic outcome. Close monitoring of Paco2 is necessary during sedation via anesthetic conserving device.

1Department of Nephrology and Medical Intensive Care, Charité-Universitätsmedizin Berlin, Berlin, Germany.

2Department of Neurology, Chariteé-Universitätsmedizin Berlin, Berlin, Germany.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (http://journals.lww.com/ccmjournal).

Dr. Leithner has received remuneration for presentations and travel costs from C.R. BARD and Zoll. He received funding from Bard Medical. Dr. Jörres received funding from Fresenius Medical Care (Consultancy). Dr. Storm has received remuneration for presentations, travel costs and partial technical or material support from Philips, C.R.BARD, Zoll, Medivance, COVIDIEN, Nonin Medical, and a grant from the German Heart Foundation. The remaining authors have disclosed that they do not have any potential conflicts of interest.

For information regarding this article, E-mail: christian.storm@charite.de

Copyright © 2016 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.